8 key arguments, take-homes on day 1 of FDA stem cell meeting

Randy-Mills-CIRM-FDA

Today was the first part of the FDA’s 2-day meeting on stem cell draft guidances. It was a great meeting I thought. A few consistent themes and notable things emerged as raised by participants.